Actively Recruiting
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Led by Sirius Therapeutics Co., Ltd. · Updated on 2026-04-29
104
Participants Needed
1
Research Sites
194 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.
CONDITIONS
Official Title
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to comprehend and willing to sign an informed consent form and follow study rules
- Male or female aged 18 to 75 years
- Body mass index between 18.0 and 35.0 kg/m2
- History of chronic coronary artery disease and/or peripheral arterial disease
You will not qualify if you...
- Known bleeding disorder
- Severe heart failure with left ventricular ejection fraction less than 35% or NYHA class III or IV symptoms
- Genetic or non-ischemic cardiomyopathies unrelated to atherosclerotic cardiovascular disease
- History of ethanol abuse or drug addiction (cannabis allowed) within 6 months before screening
- Use of any investigational drug within 30 days or 5 half-lives before study dosing
- Previous use of SRSD107
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fuwai Hospital
Beijing, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here